Form 4: TScan Therapeutics Director Gabriela Gruia Acquires Stock Options

Director Gabriela Gruia acquired stock options for 47,500 shares of TScan Therapeutics, Inc.

Summary

• On June 12, 2024, Gabriela Gruia, a director of TScan Therapeutics, Inc., acquired stock options for 47,500 shares.
• The exercise price of the options is $8.88 per share.
• The options vest fully on the earlier of June 12, 2025, or the next annual meeting of the Issuer's stockholders, contingent upon continued service.
• Following the transaction, Gruia directly owns options for 47,500 shares.

Sentiment

Score: 7

Explanation: The acquisition of stock options by a director is generally viewed positively as it aligns their interests with the company's success. It suggests confidence in the company's future prospects.

Positives

• Acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting of the options is contingent upon continued service, aligning the director's interests with the company's long-term success.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value.

Comparison to Industry Standards

• Stock option grants are a typical component of compensation packages for directors and executives in biotech companies.
• Companies like Amgen, Gilead, and Biogen also use stock options as part of their compensation strategy to incentivize performance and align interests with shareholders.
• The vesting schedule and exercise price are generally in line with industry standards for similar-sized companies.

Stakeholder Impact

• The stock option grant could positively impact shareholders if the director's performance leads to increased company value.
• Employees may view the grant as a positive sign of the company's commitment to its leadership.

Key Dates